Genzyme Campath MS Launch Could Be Delayed Two Years
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III studies of the CLL therapy in multiple sclerosis are targeted to begin in the second half, Genzyme tells “The Pink Sheet” DAILY.
You may also be interested in...
Genzyme/Bayer Get FDA Approval For Campath As First-Line Treatment In Lymphocytic Leukemia
Bayer, who markets the mAb, does not plan any expansion of its 90-strong U.S. sales force in light of the label extension, firm tells “The Pink Sheet” DAILY.
Genzyme/Bayer Get FDA Approval For Campath As First-Line Treatment In Lymphocytic Leukemia
Bayer, who markets the mAb, does not plan any expansion of its 90-strong U.S. sales force in light of the label extension, firm tells “The Pink Sheet” DAILY.
Genzyme’s Tolevamer Misses Endpoint In First Of Two Phase III Studies
“We don’t believe tolevamer will be commercialized in the near future,” Genzyme tells “The Pink Sheet” DAILY.